If safety and efficacy are adequately proven, clinical trials can stop at this point, and the NCE can move into the New Drug Application (NDA) phase to begin marketing.
Ikiwa usalama na ufanisi umethibitishwa vizuri, vipimo vya kliniki vinaweza kukoma katika hatua hii na NCE kuendendelea na hatua ya matumizi ya dawa mpya ili kuanza uuzaji.